Safe administration of iodine-131 tositumomab after repeated infusion-related reactions to rituximab

Oncologist

Volumn 12, Issue 3, 2007, Pages 338-340

  Hayslip, John ^a,b   Fenning, Robert ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b CSB 903 ^*  (United States)

Author keywords

Adverse effects; Antibodies; Follicular lymphoma; Monoclonal; Radioimmunotherapy

Indexed keywords

ADRENALIN; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; PARACETAMOL; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE;

ADULT; ARTICLE; BONE MARROW BIOPSY; CANCER GRADING; CASE REPORT; CHILL; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG SAFETY; DYSPNEA; FOLLICULAR LYMPHOMA; HUMAN; HUMAN TISSUE; INJECTION SITE REACTION; LYMPHADENOPATHY; LYMPHOCYTE COUNT; MALE; PLEURA EFFUSION; PRIORITY JOURNAL; SENSORY NEUROPATHY; SINGLE DRUG DOSE; THORACOCENTESIS; WHEEZING;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHOMA; MALE; PREDNISONE; SELF ADMINISTRATION; VINCRISTINE;

EID: 34147183787     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-3-338     Document Type: Article

References (14)

1. McLaughlin P, Hagemeister FB, Grillo-Lopez AJ. Rituximab in indolent lymphoma: The single-agent pivotal trial. Semin Oncol 1999;26(suppl 14):79-87.
2. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005;31:456-473.
3. Mohrbacher A. B cell non-Hodgkin's lymphoma: Rituximab safety experience. Arthritis Res Ther 2005;7(suppl 3):S19 -S25.
4. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-2833.
5. Hainsworth JD, Litchy S, Burris HA 3rd et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002;20:4261-4267.
6. Saito B, Nakamaki T, Adachi D et al. Acute respiratory distress syndrome during the third infusion of rituximab in a patient with follicular lymphoma. Int J Hematol 2004;80:164-167.
7. Montero AJ, McCarthy JJ, Chen G et al. Acute respiratory distress syndrome after rituximab infusion. Int J Hematol 2005;82:324-326.
8. Lim LC, Koh LP, Tan P. Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia. J Clin Oncol 1999;17:1962-1963.
9. Byrd JC, Murphy T, Howard RS et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001;19:2153-2164.
10. Byrd JC, Waselenko JK, Maneatis TJ et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 1999;17:791-795.
11. Winkler U, Jensen M, Manzke O et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999;94:2217-2224.
12. Zelenetz AD. A clinical and scientific overview of tositumomab and iodine I 131 tositumomab. Semin Oncol 2003;30(suppl 4):22-30.
13. Horning SJ, Younes A, Jain V et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 2005;23:712-719.
14. Vose JM, Wahl RL, Saleh M et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2000;18:1316 -1323.